Analysts Anticipate Abeona Therapeutics Inc (ABEO) to Post -$0.23 Earnings Per Share
Wall Street brokerages expect Abeona Therapeutics Inc (NASDAQ:ABEO) to announce earnings of ($0.23) per share for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Abeona Therapeutics’ earnings. The lowest EPS estimate is ($0.26) and the highest is ($0.19). Abeona Therapeutics reported earnings per share of ($0.13) during the same quarter last year, which would indicate a negative year-over-year growth rate of 76.9%. The company is expected to issue its next earnings results on Wednesday, November 21st.
According to Zacks, analysts expect that Abeona Therapeutics will report full-year earnings of ($0.88) per share for the current year, with EPS estimates ranging from ($0.97) to ($0.74). For the next financial year, analysts forecast that the firm will report earnings of ($0.81) per share, with EPS estimates ranging from ($1.13) to ($0.34). Zacks’ EPS averages are a mean average based on a survey of analysts that follow Abeona Therapeutics.
Abeona Therapeutics (NASDAQ:ABEO) last posted its quarterly earnings data on Friday, August 10th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.06). The firm had revenue of $0.82 million for the quarter, compared to analyst estimates of $1.81 million. Abeona Therapeutics had a negative return on equity of 23.02% and a negative net margin of 881.74%.
Hedge funds and other institutional investors have recently modified their holdings of the stock. FMR LLC boosted its position in Abeona Therapeutics by 47.7% during the second quarter. FMR LLC now owns 7,094,307 shares of the biopharmaceutical company’s stock valued at $113,509,000 after purchasing an additional 2,291,016 shares during the last quarter. Millennium Management LLC boosted its position in Abeona Therapeutics by 5.3% during the second quarter. Millennium Management LLC now owns 964,839 shares of the biopharmaceutical company’s stock valued at $15,437,000 after purchasing an additional 48,583 shares during the last quarter. BlackRock Inc. boosted its position in Abeona Therapeutics by 0.3% during the first quarter. BlackRock Inc. now owns 1,873,472 shares of the biopharmaceutical company’s stock valued at $26,884,000 after purchasing an additional 5,094 shares during the last quarter. Nexthera Capital LP boosted its position in Abeona Therapeutics by 69.6% during the second quarter. Nexthera Capital LP now owns 626,804 shares of the biopharmaceutical company’s stock valued at $10,029,000 after purchasing an additional 257,304 shares during the last quarter. Finally, UBS Group AG boosted its position in Abeona Therapeutics by 36.5% during the first quarter. UBS Group AG now owns 152,081 shares of the biopharmaceutical company’s stock valued at $2,182,000 after purchasing an additional 40,680 shares during the last quarter. 76.24% of the stock is owned by hedge funds and other institutional investors.
Shares of ABEO stock traded up $0.37 on Monday, hitting $10.40. 629,959 shares of the stock were exchanged, compared to its average volume of 886,407. The stock has a market capitalization of $613.67 million, a P/E ratio of -15.76 and a beta of 1.10. Abeona Therapeutics has a fifty-two week low of $9.66 and a fifty-two week high of $22.00.
About Abeona Therapeutics
Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.
See Also: Bond
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.